Granules Share Price

Granules India Limited, with its corporate operations in Hyderabad, functions as a pharmaceutical manufacturing company with a unique business model of backward integration. The company was incorporated in 1984 and is headquartered in Hyderabad, Telangana. Granules India produces Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), including tablets and capsules, serving the global generic pharmaceutical market. The company operates manufacturing facilities located in Hyderabad, Vizag, and Gagillapur in Telangana, and also operates a facility in China for raw material sourcing. Granules India exports its products to over 100 countries across the globe, focusing on regulated markets including the United States, Europe, and Canada.

Granules share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes, raw material costs including chemical intermediates, capacity utilization rates across its manufacturing plants, export demand from regulated markets, and the performance of its API, PFI, and finished dosage segments. Granules stock price is influenced by various factors such as earnings, regulatory approvals from the USFDA and other global agencies, changes in pharmaceutical pricing policies, and global API price trends. In the longer run, strategies such as expansion into new therapeutic categories, backward integration into key starting materials, product portfolio diversification, and value-added product development affect the stock market perceptions. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Granules live share price provides real-time information about the last price traded, bid and ask prices, and trading volume. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Granules live price helps in observing short-term price volatility and shows how a stock moves relative to the broader Nifty Pharma and BSE Healthcare indices. Furthermore, monitoring Granules stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Granules India Limited Company Fundamentals

a. Company Background

Granules India Limited was incorporated in 1984 and is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company operates primarily in the pharmaceutical segment, supplying products across various therapeutic categories including paracetamol, ibuprofen, metformin, guaifenesin, and other widely used generic drugs. Its manufacturing operations are based in India, with major production facilities located in Hyderabad, Vizag, and Gagillapur in Telangana, while corporate functions are managed from its administrative office in Hyderabad, Telangana. The company also has a subsidiary in China for sourcing key raw materials. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and international markets, with a strong focus on the United States and Europe. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in generic pharmaceuticals, and input cost fluctuations.

b. Company Product Lines

• Active Pharmaceutical Ingredients (APIs) include paracetamol, ibuprofen, metformin, guaifenesin, methocarbamol, and other widely used generic drug ingredients serving global formulation manufacturers

• Pharmaceutical Formulation Intermediates (PFIs) are granulated or blended intermediates that serve as semi-finished products ready for compression into tablets, offering a cost-effective solution for formulation companies

• Finished Dosages (FDs) include tablets and capsules in various therapeutic categories, produced for the regulated markets of the United States, Europe, and Canada, as well as emerging markets

• Paracetamol range includes various forms of paracetamol API and its intermediates, leveraging backward integration from raw material sourcing to finished dosage

• Ibuprofen range includes ibuprofen API and its downstream products, serving the pain management therapeutic segment

• Metformin range includes metformin hydrochloride API and oral solid dosage forms for the treatment of diabetes

• Contract manufacturing services provide custom manufacturing of APIs, PFIs, and FDs for global pharmaceutical partners under long-term supply agreements

The product portfolio is structured to serve both domestic and international markets.

c. Company Revenue Model

• Export sales of APIs, PFIs, and FDs form the primary revenue source, generated through supply of pharmaceutical ingredients and finished products to generic drug manufacturers and distributors primarily in the United States, Europe, and Canada

• Domestic sales contribute revenue through supply of APIs and finished dosages to Indian pharmaceutical companies and institutions

• Contract manufacturing and strategic partnerships provide revenue through long-term supply agreements with global pharmaceutical companies for exclusive manufacturing of certain products

• Regulated market sales to the United States and Europe form a significant portion of total revenue, leveraging the company’s USFDA and EU GMP approved facilities

Revenue performance is primarily influenced by global demand for generic pharmaceuticals, raw material costs, regulatory approvals, and selling price realizations in export markets.

d. Geographic Presence

• Manufacturing facilities are located in Hyderabad, Vizag, and Gagillapur, Telangana, with an additional facility in China for raw material sourcing

• The corporate and registered office is situated in Hyderabad, Telangana

• Domestic distribution network serves pharmaceutical customers across India through direct supply channels

• Export markets include over 100 countries globally, with a primary focus on the United States, Europe, and Canada

e. Key Milestones

• 1984: Incorporation of the company

• 1990s: Expansion into API manufacturing and establishment of export capabilities

• 2000s: Capacity expansion and entry into PFI and finished dosage manufacturing

• 2015-2016: Commissioning of new manufacturing facilities and capacity enhancement

• 2025: The company announced strategic restructuring of its subsidiaries

• 2025-2026: The company faced margin pressures due to increased raw material costs and pricing pressures in the US market

• Recent years: Continued focus on product portfolio diversification, backward integration, and operational efficiency improvements

f. Industry Perspective

The pharmaceutical API and formulation manufacturing industry is research-intensive and closely linked to demand from global generic drug manufacturers, healthcare providers, and distribution channels. Demand trends are influenced by patent expirations of blockbuster drugs, the growth of generic pharmaceutical markets, increasing healthcare access, and population demographics.

The industry is also affected by fluctuations in raw material prices such as chemical intermediates and solvents, along with energy and logistics costs. Regulatory compliance with quality standards from agencies like USFDA, WHO-GMP, and European authorities increasingly shapes production practices and capital investment decisions.

Companies in the sector must manage patent expirations, intense global competition from Chinese and Indian API manufacturers, pricing pressure from buyers, and regulatory compliance while maintaining operational efficiency. These factors collectively influence financial performance and investor perception of firms like Granules India.

Granules India Limited Stock Market Presence: Listings & Index Representation

Granules India Limited is listed on the National Stock Exchange (NSE) under the symbol GRANULES and on the Bombay Stock Exchange (BSE) with the scrip code 532482. Granules share price is actively traded on both exchanges. The company’s market presence is within the mid-cap segment of the market. Due to its size and sector focus, Granules stock price is generally tracked by investors interested in the API and pharmaceutical formulation manufacturing industry.

Granules India Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a mid-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the Nifty Midcap 100 and Nifty Pharma indices. Granules share price finds representation in these indices based on its market standing. Granules stock price presence in these indices helps investors track the company relative to other API and pharmaceutical formulation manufacturing companies.

Granules India Limited Stock Performance and Share Price History

Granules share price today on the NSE reflects its position as a vertically integrated pharmaceutical manufacturer with a strong presence in the paracetamol and ibuprofen value chains. Its performance is qualitatively driven by factors such as production capacity utilization across its manufacturing facilities, management of raw material costs including chemical intermediates, growth in export sales to regulated markets, and the ability to maintain regulatory compliance with global quality standards. Investors compare the Granules share price movement with other API and pharmaceutical formulation companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported Granules share price. Beyond operational and sector influences, corporate actions such as the company’s strategic backward integration into key starting materials and its expansion into new therapeutic categories can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by USFDA inspections, drug pricing policies, and global API demand cycles.

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by the stock’s annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger export demand and stable raw material margins, whereas a significant low aligns with market corrections or sector volatility. Granules share price extremes reflect the impact of regulatory actions, global pharmaceutical pricing trends, and earnings visibility, providing a framework for understanding historical performance.

Granules stock price behaviour mirrors the trading patterns of a mid-cap pharmaceutical company within India’s API manufacturing ecosystem. The company’s diversified portfolio spanning APIs, PFIs, and finished dosages has shaped its price history. Over recent years, Granules share price has experienced periods of sharp gains driven by strong export orders and USFDA approvals, followed by phases of consolidation amid pricing pressures and raw material cost inflation. The stock has shown a certain level of volatility compared to the broader market, aligning with the cyclical nature of the API industry.

The company’s performance has closely tracked global generic API demand and raw material cost cycles for chemical intermediates. Positive momentum appeared during periods of increased generic drug consumption, supply disruptions from China, and favourable currency movements that boosted export realizations. However, periods of raw material cost inflation, intense competition from Chinese API manufacturers, and pricing pressure from buyers have led to consolidation in Granules share price. Profitability has shown patterns aligned with the company’s ability to manage input costs and pass through price increases to customers.

Despite global supply chain disruptions, Granules shares showed resilience during challenging periods. While the broader pharmaceutical sector faced headwinds from input cost inflation, the company’s integrated business model and multiple manufacturing locations helped Granules share price navigate industry cycles. The company maintains a significant workforce and exports to over 100 countries worldwide. It has also operated at healthy capacity utilization levels across its manufacturing plants.

Granules share price has declined for several recurring reasons. A drop in global generic API demand or pricing pressure from formulation buyers directly impacts profitability and leads to selling pressure. Changes in government policy regarding API import restrictions or manufacturing quality standards can also cause Granules share price to fall. Moreover, increases in operational costs without matching price increases compress margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export order volumes, leading to price declines. The stock remains sensitive to raw material price movements; if chemical intermediate costs rise significantly, it can cause Granules share price to fall as investors adjust expectations for future margin growth. Broader market sell-offs in mid-cap stocks also pull Granules share price down, regardless of the company’s individual performance. Delays in regulatory approvals for new product registrations or warning letters from the USFDA can also weigh on investor sentiment, resulting in lower valuation.

Granules India Limited Investor Relevance and Role in Portfolio

Granules India Limited is a holding in mid-cap and pharmaceutical sector portfolios, offering exposure to API, PFI, and finished dosage manufacturing with a focus on regulated markets like the United States and Europe. Its inclusion in pharma indices underscores its importance in India’s generic pharmaceutical manufacturing space. The company’s position as a vertically integrated player in the paracetamol and ibuprofen value chains, together with its multiple manufacturing facilities and export reach to over 100 countries, makes it a consideration for long-term allocations.

Granules share price receives influence from the company’s ownership structure. Granules India equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of around 43 percent of the company’s total shares, reflecting strong internal control. Foreign institutional investors hold a notable portion of the company’s shares, with holdings around 30 to 35 percent. Domestic institutional investors maintain a modest holding. Mutual funds also hold a stake. The public holds the remaining share. The company’s management includes Krishna Prasad Chigurupati as Chairman and Managing Director. This investor base, with stable promoter participation and significant institutional ownership, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on API and pharmaceutical formulation manufacturing.

Beyond fundamentals and ownership, the stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on raw material prices, export orders, and regulatory policy actions from the USFDA and other global agencies. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in US drug pricing policies or import alerts.

Technical indicators provide additional insight into short-term momentum shifts in Granules stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s beta indicates a certain level of volatility compared to the broader market. The company’s debt to equity ratio of around 0.44 reflects a moderate use of leverage. Return on equity and return on capital employed are at certain levels, and the company’s book value per share is a reference point for valuation.

Overall, Granules India demonstrates a certain volatility profile compared to the broader market, with the stock generally considered to have moderate systematic risk. This makes it responsive to broader market movements and sector-specific factors such as raw material price fluctuations, regulatory approvals, and global API demand cycles.

Granules India Limited Sectoral Relevance and Peer Positioning

Granules India Limited sector relevance stems from its over four-decade presence in the pharmaceutical API and formulation industry since 1984, its position as a vertically integrated manufacturer of APIs, PFIs, and finished dosages, its significant presence in the paracetamol, ibuprofen, metformin, guaifenesin, and methocarbamol value chains, its manufacturing facilities located in Hyderabad, Vizag, and Gagillapur in Telangana, its additional sourcing facility in China, its strong export focus with products reaching over 100 countries including regulated markets like the United States, Europe, and Canada, and its multiple USFDA, WHO-GMP, and EU GMP certifications, establishing it as a focused mid-cap API and formulation provider supporting India’s generic pharmaceutical export ecosystem. Peer comparisons with companies like Aarti Drugs, Solara Active Pharma Sciences, IOL Chemicals, Ind-Swift Laboratories, and other API-focused pharmaceutical companies focus on regulatory certifications, product mix, export intensity, and value-added formulation diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API molecule pricing, global generic drug demand trends, and government pharmaceutical manufacturing policies further highlights Granules India positioning within India’s broader API manufacturing market.

Granules market cap highlights its position as a mid-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization fluctuates within a range depending on the reporting period. The market cap has moved in line with investor perceptions of the company’s growth potential following its capacity expansions and strategic restructuring. From earlier years through more recent periods, Granules market cap showed an increasing trend as the company expanded its manufacturing capacity and diversified its product portfolio, followed by phases of consolidation due to margin pressures and competitive intensity. This pattern reflects investor confidence during favourable generic drug cycles with strong demand for affordable medicines, followed by contraction during challenging periods impacted by intense competition from Chinese API manufacturers and rising input costs. This decrease mirrors the correction in the share price from its annual high to recent levels.

Granules earnings trajectory demonstrates the impact of its operational execution in a competitive global API industry. In recent fiscal years, total income showed trends supported by the core API, PFI, and finished dosage business. Based on available data, the company’s revenue from operations increased from previous fiscal periods to more recent periods, supported by strong export demand. However, profit after tax has shown variability, impacted by raw material cost inflation and pricing pressures. The company announced a strategic restructuring of its subsidiaries to streamline operations. Granules earnings have faced headwinds from fluctuating raw material costs, competitive pressures from international API producers, and pricing pressure from buyers, especially in the highly competitive paracetamol market. However, the company has expanded its product portfolio and invested in backward integration to strengthen its market position, and expects growth from capacity expansions and high-value product registrations.

Granules EPS provides insight into its operational performance and income generation from API sales, PFI, and finished dosages. The company reported certain levels of basic EPS in recent quarters that showed movement compared to previous quarters and corresponding quarters of prior years, reflecting the impact of margin pressures. The trailing twelve-month EPS stands at certain levels depending on the reporting period. Granules EPS for recent full fiscal years showed patterns compared to prior fiscal years, reflecting the impact of demand cycles, regulatory approvals, and cost structures. The company has a face value per share and continues to be promoted by the Chigurupati family.

Granules P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API sales, PFI, and finished dosages. Based on available data, the current P/E ratio stands at a certain level compared to the industry average, often trading at a moderate multiple reflecting the competitive landscape for commoditized APIs. The company’s profit after tax has shown patterns from previous fiscal years to the most recent fiscal year. Quarterly performance has demonstrated mixed movement, with profit after tax showing variability from earlier quarters to later quarters, accompanied by movement in total income on a quarter-on-quarter basis. Granules P/E ratio reflects how market sentiment evolves alongside the company’s operational performance in a competitive global industry. The company’s earnings before interest and taxes for recent quarters stood at certain levels reflecting operating efficiency impacted by market conditions. The net profit margin has shown movement in recent quarters compared to same quarters of prior years, indicating how the company manages cost structures and pricing power in a competitive API market.

Summary

Granules India Limited operates as a mid-cap vertically integrated API, PFI, and finished dosage manufacturer with a history spanning over four decades. Granules share price gets influenced by global demand for generic APIs, raw material costs, regulatory approvals from agencies like the USFDA, and the company’s export performance to over 100 countries. The company’s strong presence in the paracetamol value chain, its multiple manufacturing facilities, and its backward integration strategy support its market position. Granules stock price reflects operational execution within the competitive API manufacturing sector. The ownership structure shows promoter holding of around 43 percent with significant institutional participation and a retail minority.